Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells(15 views visite) Capasso D, Borbone N, Terracciano M, Di Gaetano S, Piccialli V
Mar Drugs (ISSN: 1660-3397linking), 2020 Jul 29; 18(8): N/D-N/D.
Keywords Parole chiave: A375 And Hela Cell Lines, C15 Acetogenins, Mycalin A, Antiproliferative Activity, Synthetic Analogues
Affiliations Affiliazioni: *** IBB - CNR ***
CESTEV, University of Naples Federico II, 80145 Naples, Italy.
Department of Pharmacy, University of Naples Federico II, 80131 Naples, Italy.
Institute of Biostructures and Bioimaging, CNR, 80134 Naples, Italy.
Department of Chemical Sciences, University of Naples Federico II, 80126 Naples, Italy.
References Riferimenti: Not available. Non disponibili.
Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells
Mycalin A, a polybrominated C(15) acetogenin isolated from the encrusting sponge Mycale rotalis, displays an antiproliferative activity on human melanoma (A375) and cervical adenocarcinoma (HeLa) cells and induces cell death by an apoptotic mechanism. Various analogues and degraded derivatives of the natural substance have been prepared. A modification of the left-hand part of the molecule generates the most active substances. A structurally simplified lactone derivative of mycalin A, lacking the C1-C3 side chain, is the most active among the synthesized compounds exhibiting a strong cytotoxicity on both A375 and HeLa cells but not but not on human dermal fibroblast (HDF) used as healthy cells. Further evidence on a recently discovered chlorochromateperiodate-catalyzed process, used to oxidise mycalin A, have been collected.
Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells
No results. Nessun risultato.
Antiproliferative Activity of Mycalin A and Its Analogues on Human Skin Melanoma and Human Cervical Cancer Cells
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(207 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
17 Records (16 escludendo Abstract e Conferenze). Impact factor totale: 53.883 (50.649 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 44.449 (40.747 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Gennaro Angrisano on in data Thursday 14 January 2021, 17:25:47 15 views visite. Last view on Ultima visita in data Friday 26 February 2021, 6:54:41